CimaVax-EGF

InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

Retrieved on: 
Tuesday, June 8, 2021

The Phase II clinical trial is expected to enroll approximately 70 patients at sites in Europe, the U.S. and elsewhere.

Key Points: 
  • The Phase II clinical trial is expected to enroll approximately 70 patients at sites in Europe, the U.S. and elsewhere.
  • The study will investigate two independent arms: vilobelimab alone and vilobelimab in combination with pembrolizumab.
  • Dr. Korinna Pilz, Global Head of Clinical Research and Development at InflaRx, said: We are pleased to initiate the first clinical trial to evaluate vilobelimab in cancer.
  • Approximately 300 people have been treated with vilobelimab in clinical trials, and the antibody has been shown to be well tolerated.

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Retrieved on: 
Monday, November 9, 2020

At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.

Key Points: 
  • At the time of analysis, 123 patients with advanced cancers had been treated with cosibelimab and were evaluable for safety.
  • Cosibelimab appeared to be safe and well-tolerated with a potentially favorable safety profile as compared to anti-PD-1 therapies currently available.
  • A copy of the poster presentation is available on the Publications page of the Pipeline section of Checkpoints website, www.checkpointtx.com .
  • According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2020, and non-small cell lung cancer accounts for 80-85% of all lung cancers.

PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC

Retrieved on: 
Monday, August 3, 2020

Olinvacimab, the leading clinical candidate being developed by PharmAbcine, has shown impressive safety profile and efficacy in clinical studies.

Key Points: 
  • Olinvacimab, the leading clinical candidate being developed by PharmAbcine, has shown impressive safety profile and efficacy in clinical studies.
  • It is currently in a phase II clinical trial in Australia and USA in bevacizumab non responding rGBM patients.
  • In addition, two phase Ib combination trials of olinvacimab and pembrolizumab are ongoing in mTNBC and in rGBM patients.
  • Thisstudy will give us a tremendous opportunity to explore an optimal combination of angiogenesis regulator and 3rd generation EGFR inhibitor to treat NSCLC."

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer - Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 14, 2020

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Epidermal growth factor receptor-Non Small Cell Lung Cancer?

Key Points: 
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Epidermal growth factor receptor-Non Small Cell Lung Cancer?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Epidermal growth factor receptor-Non Small Cell Lung Cancer?
  • Quantify patient populations in the global Epidermal growth factor receptor-Non Small Cell Lung Cancer market to improve product design, pricing, and launch plans
    The Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.
  • Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
    4.1.

PDC*line Pharma Announces the Administration of a First Patient With Its Therapeutic Cancer Vaccine Candidate (PDC*lung01) Targeting Non-small Cell Lung Cancer

Retrieved on: 
Tuesday, March 3, 2020

This patient is under the supervision of Dr. Anne Sibille, principal investigator for the Liege University Hospital (Belgium).

Key Points: 
  • This patient is under the supervision of Dr. Anne Sibille, principal investigator for the Liege University Hospital (Belgium).
  • A total of 62 evaluable HLA-A*02:01 positive NSCLC patients are expected in three clinical centers in Belgium and six in France.
  • We are delighted to have achieved this first important milestone in the clinical development of PDC*line Pharma with our lead cancer vaccine candidate, said Eric Halioua, president and CEO of PDC*line Pharma.
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing 80% of cases.

OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with TedopiĀ®

Retrieved on: 
Monday, November 11, 2019

The results presented demonstrated that in advanced non-small cell lung cancer (NSCLC) patients, survival was significantly prolonged in patients immunized with the combination of neoepitopes used in Tedopi.

Key Points: 
  • The results presented demonstrated that in advanced non-small cell lung cancer (NSCLC) patients, survival was significantly prolonged in patients immunized with the combination of neoepitopes used in Tedopi.
  • "The new exploratory data from translational analysis demonstrate that neoepitope combination Tedopi increases the recognition of cancer cells by antigen-specific CD8 T cellswith a favorable correlation with patients survival.
  • We are encouraged by these findings and look forward to confirming the correlation between neoepitope response and survival in further translational investigations," said Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics.
  • Tedopi, a combination of neoepitopes, is currently being evaluated in an open-label Phase 3 trial in advanced NSCLC for HLA-A2 positive patients who failed previous treatments with checkpoint inhibitors.